Articles

Dr David Spigel talks about currently available and emerging biomarkers that predict the greatest sensitivity to immunotherapy, including his insight into PD-L1, MSI, and TMB. Read More ›

Dr David Spigel discusses how medical oncologists and the rest of the cancer care team can best communicate with pathologists to help make informed treatment decisions for individual patients and set up new assays for emerging biomarkers as they are discovered. Read More ›

Dr David Spigel reviews 3 of the most important, practice-changing topics at ASCO 2018: new therapies targeting RET in a number of tumor types, a prognostic biomarker assay to predict whether patients with breast cancer will need adjuvant hormonal therapy or chemotherapy, and the minimum level of PD-L1 positivity required to predict outcomes with immunotherapy in lung cancer. Read More ›

Dr David Spigel considers how patient-reported outcomes, as well as palliative and supportive care, are revolutionizing cancer care so that consideration is being given to treating the patient, not just the cancer. Read More ›

Dr David Spigel discusses the 2 major themes highlighted at ASCO 2018: the use of cancer biomarkers to achieve precision therapy, and fine tuning treatment of patients with immunotherapy with respect to who to treat, how to treat, and how to predict clinical outcomes. Read More ›

Dr Thomas Bachelot is careful to set reasonable expectations for his patients with HR+/HER2- metastatic breast cancer regarding how long their treatment will last and how it will impact them. Read More ›

Hope Rugo, MD, discusses common presenting symptoms of HR+/HER2- metastatic breast cancer, citing bone metastasis as the most prevalent. Read More ›

An increased understanding of the genomic and molecular underpinnings of cancer pathogenesis and their exploitation in the development of targeted therapies has revolutionized the treatment of many cancer types including BRAF-mutant melanoma, HER2-amplified breast cancer, and non–small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase rearrangements.

Read More ›

Biomarkers are critical for the personalization of therapy in oncology. It is quite clear that all therapies, no matter how potent, will require some personalization to reach their maximum effect.

Read More ›

As discussed in the main article in this publication, the use of biomarkers has revolutionized the treatment of many types of cancer in a very personalized way, and has significantly affected the entire cancer care team, including (but not limited to) oncologists, oncology nurses, oncology nurse navigators, surgical and clinical pathologists, and pharmacists.

Read More ›